A glimmer of hope emerged for Asian elephants with the trial of the first mRNA vaccine against Elephant Endotheliotropic Herpesvirus (EEHV) at the Houston Zoo.
Tess, a 40-year-old elephant, received the vaccine in June, following a wave of deaths in young captive elephants attributed to the virus.
Developed by Dr. Paul Ling, the mRNA vaccine mirrors the technology used in COVID-19 vaccines. It aims to train young elephants’ immune systems to recognize and fight EEHV, a potentially fatal herpes virus.
Similar to Ebola in humans, EEHV can cause hemorrhagic disease with a devastating 70% mortality rate in symptomatic elephants, spreading through trunks, and posing a significant threat in captive populations.
EEHV is a major concern for zookeepers and conservationists; Recent fatalities in zoos worldwide highlight the virus’s impact on captive breeding programs, which are crucial for the survival of this endangered species.
While EEHV is present in wild populations, its effects still need to be understood. Vaccinating wild elephants presents logistical challenges, making captive programs even more critical.
With fewer than 50,000 Asian elephants remaining in the wild, threats like habitat loss, poaching, and genetic isolation further endanger their future.
Researchers are cautiously optimistic and Tess’s health is being closely monitored, and if no adverse reactions occur, more elephants could be vaccinated later this year.
This collaborative effort between the Houston Zoo, Baylor College of Medicine, and Colossal represents a significant step forward in elephant conservation.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.